MedTrace Logo

Evaluation of AZR-MD-001 in Patients With Meibomian Gland Dysfunction (MGD)

NCT04391959 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 31

Last updated 2022-05-16

Study results available
· View outcomes & findings →

Summary

AZ202001 is a multicenter study of AZR-MD-001 ointment and AZR-MD-001 vehicle in patients with Meibomian Gland Dysfunction (MGD)

Conditions

  • Meibomian Gland Dysfunction

Interventions

DRUG

AZR-MD-001 Active

AZR-MD-001 is an active ophthalmic ointment

DRUG

AZR-MD-001 Vehicle

AZR-MD-001 is a vehicle ophthalmic ointment

Sponsors & Collaborators

  • Avania

    collaborator INDUSTRY

  • Azura Ophthalmics

    lead INDUSTRY

Principal Investigators

  • Jacqueline Tan-Showyin · School of Optometry and Vision Science, University of New South Wales

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-07-17
Primary Completion
2021-01-06
Completion
2021-01-06

Countries

  • Australia
  • New Zealand

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04391959 on ClinicalTrials.gov